d-Cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
It has been long thought that hyper-activation of N-methyl-D-aspartate (NMDA) receptors underlies neurological decline after traumatic brain injury. However, all clinical trials with NMDA receptor antagonists failed. Since NMDA receptors are down-regulated from 4h to 2 weeks after brain injury, activation at 24h, rather than inhibition, of these receptors, was previously shown to be beneficial in mice. Here, we tested the therapeutic window, dose regimen and mechanism of action of the NMDA receptor partial agonist D-cycloserine (DCS) in traumatic brain injury. Male mice were subjected to trauma using a weight-drop model, and administered 10 mg/kg (i.p) DCS or vehicle once (8, 16, 24, or 72h) twice (24 and 48h) or three times (24, 48 and 72h). Functional recovery was assessed for up to 60 days, using a Neurological Severity Score that measures neurobehavioral parameters. In all groups in which treatment was begun at 24 or 72h neurobehavioral function was significantly better than in the vehicle-treated groups. Additional doses, on days 2 and 3 did not further improve recovery. Mice treated at 8h or 16h post injury did not differ from the vehicle-treated controls. Co-administration of the NMDA receptor antagonist MK-801 completely blocked the protective effect of DCS given at 24h. Infarct volume measured by 2,3,5-triphenyltetrazolium chloride staining at 48h or by cresyl violet at 28d was not affected by DCS treatment. Since DCS is used clinically for other indications, the present study offers a novel approach for treating human traumatic brain injury with a therapeutic window of at least 24h.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Role of Excitatory Amino Acids and NMDA Receptors in Traumatic Brain Injury
Faden, A. I., Demediuk, P., Panter, S. S., & Vink, R. (1989) · Science · doi:10.1126/science.2567056 · Cited by 1,508 · cited 1×
“…past few decades, hyperactivation of the NMDA receptors by extracellular excitatory amino acids such as glutamate had been implicated in the cellular events leading to neuronal death and decline in function following traumatic or ischemic brain injury (e.g. Faden et al., 1989; Hayes et al., 1988).”
Influential(1999) · doi:10.1097/00001199-199912000-00009 · Cited by 1,387 · cited 1×
“Traumatic brain injury, the leading cause of mortality and disability among young people in the Western world (see, Thurman et al., 1999, Myburgh et al., 2008, Koskinen et al., 2008) triggers a large, transient increase in excitatory amino acid efflux (especially glutamate) in the brain of…”
Clinical trials in head injury
Narayan, R. K., Michel, M. E., Ansell, B., Baethmann, A., Biegon, A., Bracken, M. B., Bullock, M. R., Choi, S. C., Clifton, G. L., Contant, C. F., et al. (2002) · Journal of Neurotrauma · doi:10.1089/089771502753754037 · Cited by 913
Self-citationFactors affecting excitatory amino acid release following severe human head injury
Bullock, R., Zauner, A., Woodward, J. J., Myseros, J., Choi, S. C., Ward, J. D., Marmarou, A., & Young, H. F. (1998) · Journal of Neurosurgery · doi:10.3171/jns.1998.89.4.0507 · Cited by 526
Consolidation of Human Motor Cortical Neuroplasticity by D-Cycloserine
Nitsche, M. A., Jaussi, W., Liebetanz, D., Lang, N., Tergau, F., & Paulus, W. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300517 · Cited by 385
Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder
Heresco-Levy, U., Kremer, I., Javitt, D. C., Goichman, R., Reshef, A., Blanaru, M., & Cohen, T. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003061 · Cited by 134 · cited 2×
“…established in clinical use as an antimicrobial drug (Heifets 1994) in some infectious diseases, is also used as a " cognitive enhancer " in several chronic neurological disorders, including Alzheimer's disease and schizophrenia (Duncan et al. 2004; Heresco-Levy et al., 2002; Laake et al., 2002).”
Cited by
Craniotomy: True Sham for Traumatic Brain Injury, or a Sham of a Sham?
Cole, J. T., Yarnell, A., Kean, W. S., Gold, E., Lewis, B., Ren, M., McMullen, D. C., Jacobowitz, D. M., Pollard, H. B., O'Neill, J. T., et al. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2010.1427 · Cited by 296
D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review
Schade, S., & Paulus, W. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv102 · Cited by 135
The cytokine temporal profile in rat cortex after controlled cortical impact
Dalgard, C. L., Cole, J. T., Kean, W. S., Lucky, J. J., Sukumar, G., McMullen, D. C., Pollard, H. B., & Watson, W. D. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00006 · Cited by 121
Neuroprotective effect of picroside II in brain injury in mice.
(2016) · PubMed Central · Cited by 2
Metadata
- Authors
- Adeleye, A., Shohami, E., Nachman, D., Alexandrovich, A., Trembovler, V., Yaka, R., Shoshan, Y., Dhawan, J., & Biegon, A.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 629
- Issue
- 1-3
- Pages
- 25-30
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2069024481
- Cited by
- 41
- References
- 6
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: d-Cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window. https://app.cochat.ai/papers/10.1016/j.ejphar.2009.11.066
- The paper
- Adeleye, A., Shohami, E., Nachman, D., Alexandrovich, A., Trembovler, V., Yaka, R., Shoshan, Y., Dhawan, J., & Biegon, A. (2010). d-Cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2009.11.066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.